BOCA RATON, Fla, March 03, 2016 -- RxStrategies, Inc. is pleased to announce the appointment of Russell Crane to the new position of Sales Manager - Northeast Region. He joins the RxStrategies’ sales team and has responsibility for sales and delivery of customized 340B pharmacy administration and split billing solutions to providers located in the Northeast Region.
"I am very pleased to welcome Russell to the RxStrategies’ team,” said Fenton Markevich, Chief Executive Officer for RxStrategies. “We look forward to incorporating Russell’s market and product expertise and knowledge for the benefit of our existing and future clients. We believe that Russell will be a strong addition and will complement our current market facing sales and account management teams.”
Russell joins RxStrategies with strong pharmacy industry background, with a particularly strong presence in the Northeast in market facing roles to the pharmacy administration and 340B markets. Russell is a graduate of Northeastern University.
"RxStrategies has a strong reputation in the marketplace with both a unique and transparent processing solution, and a proprietary split billing solution for this complex market," said Crane. "I am excited to join a growing industry leader and bring value to clients and prospects by using a consultative approach. I look forward to continuing that tradition by providing 340B guidance and insight to our current and future clients."
About RxStrategies, Inc.
Established in 2003 and headquartered in Boca Raton, Florida, RxStrategies, Inc. provides accountability, transparency and value-based solutions for the Federal 340B Drug Pricing Programs. As a full-service 340B Drug Pricing Program services organization, RxStrategies provides a diverse range of services to all “Qualified Entities” and the in-house and/or contract pharmacies, including 340B administration, split billing, orphan drug, and audit services. RxStrategies’ “real-time” comprehensive solutions are designed to meet the challenges of regulatory compliance, patient eligibility, pharmacy replenishment, program tracking and reporting of the Federal 340B Drug Pricing Program. To learn more, please visit www.340Bplus.com.
Media Contact: Cheryl Musial, Media Relations, Mopdog, Inc. [email protected] 678-737-7325


Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 



